TRACON Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Reuters05-15

* TRACON Pharmaceuticals Inc reported a quarterly adjusted loss of $1.33​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-7.20. The mean expectation of two analysts for the quarter was for a loss of $1.19 per share. Wall Street expected results to range from $-1.20 to $-1.18 per share.

* Revenue was $100.00 thousand​; analysts expected zero.

* TRACON Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.33​.

* The company reported a quarterly loss of $3.17 million.

* TRACON Pharmaceuticals Inc shares had fallen by 76.5% this quarter and lost 42.3% so far this year.

FORECAST CHANGES

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for TRACON Pharmaceuticals Inc is $37.50 This summary was machine generated from LSEG data May 14 at 09:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Mar. 31 2024 -1.19 -1.33 Missed

Dec. 31 2023 -1.60 0.20 Beat

Sep. 30 2023 -1.30 5.80 Beat

Jun. 30 2023 -2.00 4.40 Beat

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment